(Utkast) Kommisjonens gjennomføringsbeslutning (EU) .../... om opphevelse av gjennomføringsbeslutning (EU) 2026/1089 om utsettelse av utløpsdatoen for godkjenningen av medetomidin til bruk i biocidprodukter av produkttype 21 i samsvar med europaparlaments- og rådsforordning (EU) nr. 528/2012
Biocider: opphevelse av utsettelse av utløpsdatoen for godkjenningen av medetomidin i type 21
(Draft) Commission Implementing Decision (EU) .../... repealing Implementing Decision (EU) 2026/1089 postponing the expiry date of the approval of medetomidine for use in biocidal products of product-type 21 in accordance with Regulation (EU) No 528/2012 of the European Parliament and of the Council
Utkast til kommisjonsbeslutning godkjent av komite (representanter for medlemslandene) og publisert i EUs komitologiregister 3.11.2026
Bakgrunn
(fra kommisjonsbeslutningen)
(1) Medetomidine was approved as an active substance for use in biocidal products of product-type 21 by Commission Implementing Regulation (EU) 2015/1731 until 31 December 2022 subject to the conditions set out in the Annex to that Regulation.
(2) On 27 June 2021, an application was submitted in accordance with Article 13(1) of Regulation (EU) No 528/2012 for the renewal of the approval of medetomidine for use in biocidal products of product-type 21.
(3) Commission Implementing Decision (EU) 2022/1495 postponed the expiry date of the approval of medetomidine for use in biocidal products of product-type 21 to 30 June 2025, in order to allow sufficient time for the examination of the application. Commission Implementing Decision (EU) 2025/953 further postponed the expiry date of that approval to 30 June 2026, and Commission Implementing Decision (EU) 2026/1089 postponed again the expiry date to 31 December 2026.
(4) Commission Implementing Decision (EU) C(2026) 5001 [Publication office please insert here the number of that Decision once it is associated and the publication details in the footnote] did not renew the approval of medetomidine for use in biocidal products of product-type 21 since medetomidine does not fulfil the conditions laid down in Article 12(1) of Regulation (EU) No 528/2012.
(5) Therefore, it is appropriate to repeal Implementing Decision (EU) 2026/1089,